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The International Society for CNS Clinical Trials and Methodology (ISCTM) held its 4th Annual Autumn Conference in Toronto,
Ontario, October 6-7, 2008. The purpose of the present report is to provide an overview of one of the sessions at the conference
whichfocusedonthedesignsandmethodologiestobeappliedinclinicaltrialsofnewtreatmentsforAlzheimer’sdisease(AD)with
purported “disease-modifying” eﬀects. The session began with a discussion of how neuroimaging has been applied in multiple
sclerosis clinical trials (another condition for which disease modiﬁcation claims have been achieved). The next two lectures
provided a pharmaceutical industry perspective on some of the speciﬁc challenges and possible solutions for designing trials
to measure disease progression and/or modiﬁcation. The ﬁnal lecture provided an academic viewpoint and the closing discussion
included additional academic and regulatory perspectives on trial designs, methodologies, and statistical issues relevant to the
disease modiﬁcation concept.
Copyright © 2009 Aaron S. Kemp et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Alzheimer’s disease (AD) is a progressive, degenerative
disorder of aging that aﬀects cognition, behavior, and overall
functioning, and is associated with signiﬁcant morbid-
ity. Currently available treatments, including cholinesterase
inhibitors and an NMDA receptor antagonist, only mod-
estly enhance deﬁcient neurotransmitter systems associated
with underlying degenerative processes, and are of limited
clinical beneﬁt. As our appreciation of the underlying
pathophysiology of AD has increased substantially over
the last two decades, new targets for disease intervention
have been identiﬁed. These include processes associated
with the production, modulation, and accumulation of
amyloid-beta (Aβ) and tau. These proteins are associated
with the neuropathological features of amyloid plaques and
neuroﬁbrillary tangles, respectively, and are hypothesized
to be involved in disease processes that contribute to
progressive synaptic dysfunction, neurodegeneration, and
cell death.
Based on this expanding understanding, new molecular
entities are being developed that may disrupt a cascade of2 International Journal of Alzheimer’s Disease
events hypothesized to lead to progressive neurodegenera-
tion. As these treatments impact on more primary processes,
they could modify disease progression and oﬀer clinical
beneﬁts beyond shorter-term symptomatic improvement.
However, there are signiﬁcant challenges associated with
designing studies that will demonstrate disease modiﬁcation
and support regulatory approvals for this novel indication.
The purpose of this session was to examine some of these
challenges by ﬁrst looking at what can be gleaned from
other conditions for which disease modiﬁcation claims
have been achieved and then by identifying some of the
speciﬁc hurdles and possible solutions for designing trials in
patients with Alzheimer’s disease. Industry, academic, and
regulatory agency viewpoints were discussed, followed by
robust audience participation.
The session topic was introduced by George T. Grossberg
(St. Louis University School of Medicine) who stated that
a key question to examine, as recently posed to him by
colleague Ravi Anand (Anand Pharma Consulting) was
“Is it the molecule or is it the methodology?” He noted
that this question has particular relevance to the session
topic of trial designs, as the evaluation of innovative new
molecular entities (NMEs) for treating AD is fundamentally
bounded by the adequacy of the methodologies employed
to measure their putative eﬀects on disease progression.
Dr. Grossberg then introduced session cochair, Steven J.
Romano (Pﬁzer, Inc.), who in turn introduced the ﬁrst
lecturer, Douglas Arnold (Montreal Neurological Institute
and NeuroRx Research).
2.Lecture1: DouglasArnold
The topic of Dr. Arnold’s lecture was “The use of magnetic
resonance imaging (MRI) to measure degeneration and
progression: Lessons learned from multiple sclerosis (MS).”
Dr. Arnold, an expert in MRI and MS, stated that there
are lessons pertaining to the use of neuroimaging in the
drugdevelopmentprocessforMSwhichmightinformfuture
studies of AD progression. Dr. Arnold provided three key
points that he hoped his lecture would convey: (1) though
MRI may adequately demonstrate disease pathology, there
may be times when ﬁndings do not conform to expectations
and may necessitate a reconsideration of certain concepts
of pathogenesis; (2) MRI ﬁndings may dissociate from
clinical presentation or course and may raise questions
regarding current concepts of pathogenesis; (3) MRI may be
a predictive tool to aid in determining diagnostic speciﬁcity,
prognosis, and potential responsiveness to treatment.
Gadolinium-enhanced (Gd+) MRI of focal white-matter
inﬂammatory lesions has had a profound impact on drug
development in the ﬁeld of MS by providing sensitive mark-
ers of disease activity, and the accumulation of white matter
lesion volume also has had an important role in quantifying
the “burden” of disease and the eﬀect of disease modifying
drugs. The quantiﬁcation of new, acute lesions is more
statistically powerful than the related clinical outcome of MS
relapses, can help predict conversion to clinically deﬁnite MS
in patients who present with a ﬁrst attack suggestive of MS,
and has been partially validated as a surrogate measure of
the disease-modifying eﬀects of treatment. The implications
for AD trials include the potential for MRI to provide
biomarkers that may be more sensitive to disease progression
than clinical measures, to identify preclinical indicators of
conversion to AD, and to be more responsive to treatment
than conventional measures of change.
Advanced MRI measurements, such as whole brain
volume change, magnetization transfer ratio (MTR), T2
relaxation times, and N-acetylaspartate density (a marker
of neuronal integrity measured in vivo using magnetic
resonance spectroscopy), also may be used to provide novel
insights into the mechanisms subserving pathogenesis. For
example, these measures have been utilized to determine
whether brain volume changes following an experimental
treatment for MS, which involved immunoablation with
chemotherapy and autologous stem cell transplantation,
were more likely the result of actual tissue loss (atrophy) or
the resolution of inﬂammatory edema (pseudoatrophy). As
decreased brain volume was found to correlate with MTR
(a marker of myelin content) and not with T2 relaxation
time (a marker of water content), it was determined that
accelerated brain atrophy following chemotherapy was most
likely attributable to an actual loss of tissue. Such ﬁndings
have been crucial for dissociating treatment-related eﬀects
from disease progression in clinical trials for MS and provide
a lesson for how such MRI measurements could yield equally
valuable revelations concerning the mechanisms purported
to subserve the pathogenesis and progression of AD and
observed responses to therapy.
Another important lesson learned in the MS ﬁeld has
been that the apparent dissociation of MRI ﬁndings from
clinical presentation does not necessarily negate their poten-
tial use as markers of treatment eﬃcacy. Indeed, involvement
of “clinically silent” regions of the brain and compensatory
mechanisms such as cerebral reorganization may weaken the
associations between MRI pathology and clinical expression
but careful examination of these dissociations may further
enhance understanding of the overall course of the illness
under investigation and provide convergent evidence of
treatment eﬀects. For example, a recent meta-analysis of all
evaluabletrialspresentedbyMariaPiaSormani(SanRaﬀaele
Scientiﬁc Institute, Milan, Italy) and colleagues at the World
Congress on Treatment and Research of Multiple Sclerosis
indicated that despite a poor correlation between Gd-
enhancinglesionsandclinicalrelapsesonanindividualbasis,
the eﬃcacy of MS treatments in clinical trials as measured
by MRI and by clinical outcomes were, nonetheless, highly
correlated. Similarly, the use of MRI-based measurements in
AD clinical trials oﬀers the potential to provide measures
of disease progression that are more powerful than clinical
measures. As well, MRI can increase our understanding
of the mechanisms underlying pathogenesis, response to
treatment, and the relations of such processes to clinical
manifestations. In summary, MRI in MS has reduced the
sample size and duration of phase II trials and has provided
important biological support for disease modiﬁcation asso-
ciated with clinical eﬃcacy in phase III trials. It has potential
as a surrogate outcome, at the “trial-level,” but it is still not a
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Figure 1: Conceptual overview of the primary etiological mechanisms believed to underlie the development of Alzheimer’s disease. Black
boxes provide potential targets for interventions at various stages of the disease pathway. Image used with the permission of its creator,
Rachel Schindler (Pﬁzer, Inc.).
3. Lecture2: StevenJ. Romano
The next lecture at the session was entitled “An industry
viewpoint on clinical trial designs for disease modiﬁcation
in AD: Challenges” and was presented by Steven J. Romano
(Pﬁzer, Inc.). Dr. Romano summarized the issues to be
addressed in order to advance the development of innovative
disease modifying treatments for AD as follows: (1) disease
etiology: though much is known about the pathophysiology
of AD, there is still much that needs to be more fully
elucidated, such as the primary etiological “trigger(s)” and
where to best direct interventions; (2) disease modiﬁcation
concepts: still evolving, leaving many questions such as
whether (and to what degree) a robust, durable eﬀect is
“good enough” to qualify as “modiﬁcation”; (3) regulatory
guidance:alsostillevolving,particularlywithregardstowhat
may constitute a disease-modifying eﬀect; (4) biomarkers:
thoughpromising,nonehasbeensuﬃcientlyvalidatedtothe
extent that may be required to gain regulatory acceptance as
a surrogate endpoint; and (5) trial design: among the issues
that must be resolved are methodological and statistical
issues concerning the stratiﬁcation of the population to
be studied, the appropriate endpoints to be employed, the
durationandgeneraldesignofthetrials,andstatisticalpower
a s s u m p t i o n st oa d d r e s sd i ﬀering rates of change that may be
expected with a purported “disease-modifying” agent.
Dr. Romano noted that the “good news” is that several
central pathophysiological mechanisms believed to con-
tribute to AD have been identiﬁed and provided a brief
overview of what is currently known (summarized in
Figure 1). This expanding appreciation of AD pathophysi-
ology has allowed for the identiﬁcation of many promising
targets for a variety of putative disease-modifying treatment
approaches. These include the inhibition or modulation of
γ-andβ-secretase,tau,orcertainphosphodiesterases(PDE),
as well as novel methods to decrease amyloid deposition or
promote amyloid clearance. While this situation provides a
target-richarenaforpotentialpharmacologicalinvestigation,
many fundamental questions remain unanswered, particu-
larly regarding where best to intervene and whether a single
point or multiple points of intervention are needed to eﬀect
clinically meaningful change. Despite our purported under-
standing of AD pathophysiology, “Proof of Mechanism” has
yet to be translated into a robust “Proof of Concept” in an
appropriately powered randomized clinical trial, particularly
for any pharmacologic intervention based on the amyloid
hypothesis.
Dr. Romano then provided a brief review of the concept
of “disease modiﬁcation,” including a hypothetical graphic
depiction (Figure 2) of how this concept contrasts with
changes in level of functioning across time that would
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Figure 2: Hypothetical trajectories depicting the changes in
level of functioning across time that would be expected due
to the natural progression of AD, or with other conceptualized
interventions that would produce a symptomatic relief, a disease
modifying eﬀect, stabilization, improvement (neurorestoration), or
prevention, respectively. Image used with the permission of its
creator, Rachel Schindler (Pﬁzer, Inc.).
with other conceptualized interventions that would produce
symptomatic relief or (more optimistically) stabilization,
improvement (neurorestoration), or prevention. Among the
outstanding issues pertaining to the disease modiﬁcation
concept that still need resolution are questions about how
best to deﬁne and quantify modiﬁcation; how long it would
take to observe a treatment diﬀerence; how large an eﬀect
might be expected; whether “minor” changes that take 18–
24 months to conﬁrm are relevant; at what point in the
illnesswouldinterventionbemosteﬀective; and how to drive
academic and regulatory consensus for earlier intervention
in populations “at risk” when considering the logistical
challenges of identifying such individuals or the ethical
dilemma of whether the risks associated with treatment
exposure are justiﬁable.
Regulatory agencies serve a critically important role
in resolving many of these outstanding issues, although
guidance is still evolving. For example, although biological
evidence to support a claim of disease modiﬁcation is
required, there are to date no regulatory agency-endorsed
biomarkers of such. Though neuroimaging alone may
not suﬃce, some combination of clinical outcomes and
structural MRI (once appropriately validated) may soon
overcome this regulatory hurdle. Another challenge is the
divergence between US and European regulatory agencies
regarding the acceptance of comparisons of slopes (rates
of change) using standard parallel-arm studies. While such
designs are generally acceptable for European agencies,
the US Food and Drug Administration (FDA) appears to
prefer other designs (e.g., randomized start/withdrawal) for
demonstrating disease modiﬁcation.
An additional issue which presents a challenge to the
pharmaceutical industry is that the necessary validation of
the purported biomarkers for AD progression may end up
being conﬁrmed in rather than prior to long-term treatment
trials. Although the beneﬁts to be gained from such are
readily evident, this does present a considerable risk to the
study sponsor, particularly since so many questions still exist
concerning whether the characteristics of subpopulations
may inﬂuence the behavior of speciﬁc biomarkers, if the
utility of a given biomarker will vary across disease stages,
and (perhaps most importantly) whether changes in the
biomarker will translate into clinically meaningful beneﬁts.
Many of these questions may soon be answered by large-
scale, multi-site, longitudinal studies such as the Alzheimer’s
DiseaseNeuroimagingInitiative(ADNI),whichissupported
by joint funding from the pharmaceutical industry, private
philanthropic organizations (the Alzheimer’s Association
and the Alzheimer’s Drug Discovery Foundation), and
several federal agencies within the US Department of Health
and Human Services (including the FDA, the National
Institute on Aging, and the National Institute for Biomedical
Imaging and Bioengineering).
The ﬁnal set of challenges broached by Dr. Romano was
the speciﬁc trial design issues that must be addressed before
launching additional large-scale treatment trials. Among
the many that will require further discussion among aca-
demic, regulatory, and industry representatives to resolve are
methodological questions such as whether to use a parallel-
arm or randomized start/withdrawal designs (addressed
further below); whether the population to be studied should
be earlier-stage AD patients and whether it should be
stratiﬁed by either severity or genotype; what would be
the required duration of the trial to demonstrate disease
modiﬁcation within a minimum timeframe; which clinical,
neuroimaging, or biochemical measures are most appro-
priate to employ as either eﬃcacy or safety endpoints and
how are these to be standardized in multinational trials; and
what statistical methods or assumptions would be required
to suﬃciently power a trial to detect meaningful diﬀerences
between the natural disease progression and an unknown
degree of change associated with a novel intervention. In
closing, Dr. Romano summarized the overall implications
of the challenges he raised by stating that demonstration
of disease modiﬁcation will invariably require large, long,
costly trials; and that the signiﬁcant risks yet to be resolved
include: unprecedented mechanisms of action with as yet no
clear proof of concept, limitations of current translational
models (most models support proof of mechanism but
do not provide true disease models), a lack of suﬃcient
validation of biomarkers, the fact that regulatory guidance
is not yet harmonized or “written in stone,” and a huge
unknown regarding the potential value proposition of these
new treatments to “payers” or policy-makers within the
healthcare industry.
4.Lecture3:J. MichaelRyan
The next lecture at the session was entitled “An industry
viewpoint on clinical trials designed for demonstrating
disease progression in AD: Current approaches” and was
presented by J. Michael Ryan (Wyeth Research). Dr. Ryan
beganbyoﬀeringtheperspectivethattheindustry’sapparent
perseveration on the notion of “disease modiﬁcation” versus
symptomatic therapies is not merely a matter of “chasing
label claims” but instead reﬂects the current consensusInternational Journal of Alzheimer’s Disease 5
that supporting failing neurotransmitter systems is “just
not good enough.” By comparison, a treatment which
oﬀers disease-modifying eﬀects would actually increase in
terms of clinical beneﬁts across time by altering the natural
progression of the disease.
Emerging markers of disease progression (e.g., cere-
brospinal ﬂuid analytes, various MRI measures, or more
sensitive cognitive measures) may actually provide bet-
ter “signal strength” than traditional measures of clinical
expression, which may be “imperfect reporters of disease
state” despite having been canonized over time as eﬃcacy
endpoints. In a recent publication by Vellas et al. [1]f r o m
the European AD Consortium (EADC), the consensus of
experts and regulators on the appropriate endpoints to be
applied in various “symptomatic,” “prevention,” or “disease-
modifying” treatment trials actually shows surprisingly little
variation in the tools recommended to gauge eﬃcacy or
track progression, regardless of trial-type or the severity of
the population studied. While more innovation has been
evident in the area of cognitive assessment, more still may
be needed to improve the sensitivity of other measures of
clinicalexpression(e.g.,activitiesofdailylivingassessments).
Dr. Ryan turned next to a brief discussion of the
oft-suggested, yet rarely-executed, randomized start and
withdrawal(RS/RW)trialdesigns.Dr.Ryanpresentedﬁgures
from Leber’s [2] inﬂuential publication suggesting the utility
of these trial designs for distinguishing disease-modifying
from symptomatic treatment eﬀects. A variation on a cross-
overdesign,RS/RWdesignsemploytwosequentialtreatment
segments in which either the initiation or the withdrawal
of the experimental treatment is delayed for a randomly
selectedsubsetofsubjects.Iftheexperimentalgroup“catches
up” with the active comparison group in the RS design
or declines to the level of the placebo group in the RW
design then a symptomatic eﬀect is assumed. If, however,
the experimental group shows sustained beneﬁts relative to
the comparison groups then a disease-modifying eﬀect is
assumed. To explain why these designs have rarely been
employed on long-term AD trials, Dr. Ryan mentioned
several issues of concern which have made the industry
unwilling to fully support their usage. Speciﬁcally, he noted
that while treatment eﬀects will likely diﬀer across severity
stages of AD, the two-period dichotomy of RS/RW designs
may accentuate the impact of treatment-by-time interac-
tions. Furthermore, the fact that the optimal duration of the
delayed-withdrawal or staggered-start segments is currently
unknown;empiricalquestionsregardinghowtoestablishthe
relationships between complex pharmacokinetic, pharmaco-
dynamic, and clinical eﬀects; the concern that the negative
impact of dropouts would be ampliﬁed; and the diﬃculties
of modeling nonlinear changes in clinical outcomes, were all
mentioned as issues that have hampered the adoption of the
RS/RW designs by industry.
Reiterating some of the concerns raised earlier by Dr.
Romano regarding the critical need to validate biomarkers,
Dr. Ryan suggested the leading candidates that may even-
tually achieve surrogate status following replication across
multiple compounds and trials are volumetric MRI, cere-
brospinal levels of Aβ or tau, positron emission tomography
(PET), or ratios/combinations of these measures. For a
particular compound, these measures may be used now in
the “learn” phase of development to justify dose selection
or in “conﬁrm” phase trials as supportive data if treatment
beneﬁt is demonstrated on the primary clinical outcomes.
The European Medicines Agency (EMEA) has stated that
“ideally, proof of a disease-modifying eﬀect would require
demonstration of clinically relevant changes in key symp-
toms of the dementia syndrome and in addition supportive
evidence fora change in the underlying disease process based
on biological markers.” However, the necessary steps for the
qualiﬁcation or validation of proposed biomarkers have not
been explicitly addressed by either the EMEA or FDA. For
now, Dr. Ryan noted that the EMEA suggests a two-step
approach to the disease modiﬁcation claim: (1) “delay of
disability” based solely on clinical outcomes and (2) “full
claim for disease modiﬁcation” if a convincing biomarker
package supports the clinical outcomes.
Dr. Ryan then provided a brief overview of the rele-
vance of apolipoprotein E (APOE) and its variant subtypes
(particularly ε4). According to a recent report by Jiang
et al. [3], APOE is believed to stimulate the degradation
of Aβ in the brain, with the ε4 subtype being the least
eﬀective variant, thereby leading to greater Aβ burden
(including greater vascular deposition) among patients with
the ε4 genotype. Carriers of the APOE ε4g e n o t y p eh a v e
an increased risk of developing AD, may present an altered
course of disease progression among AD patients, and may
also show diﬀerential responses to treatment compared with
patients with other variants of APOE. For these reasons,
Dr. Ryan cautioned that future trials should be designed
to identify (and possibly stratify) participants on the basis
of whether they are carriers of the APOE ε4g e n o t y p e
(which have generally comprised approximately 60% of trial
participants).
In closing, Dr. Ryan addressed methodological and
statistical issues concerning the importance of minimizing
missing data and summarized the key topics that he felt
were critical for designing AD trials to demonstrate disease
modifying eﬀects. Citing an additional consensus report
from the EADC (Vellas et al. [4]), Dr. Ryan summarized
their recommendations (and his own) as follows: the target
population should include patients with early or mild to
moderate AD (and stratiﬁcation on the basis of APOE
genotypeshouldbeconsidered);thestudydesignshouldbea
randomized, parallel, two-arm, placebo-controlled trial of at
least 18 months in duration (or longer); proposed statistical
analyses would include a slope analysis (when not precluded
by nonlinearity in the data); primary endpoints should
be clinically relevant and include measures of cognitive
functions, functional status, neuropsychiatric symptoms,
and cost-eﬀectiveness; and secondary endpoints may include
biomarkers (biological and neuroimaging), but such are not
currently recommended as surrogate measures of primary
outcome.6 International Journal of Alzheimer’s Disease
5. Lecture4: Roger Bullock
The ﬁnal lecture at the session was entitled “An academic
viewpoint on clinical trial designs for disease modiﬁcation
in AD: Challenges” and was presented by Roger Bullock
(Kingshill Research Centre). Among the speciﬁc challenges
that Dr. Bullock mentioned would require further clari-
ﬁcation were conceptual problems with: the disease, the
science, the investigational products, the methodology, and
the drug development process. For each of these conceptual
challenges, Dr. Bullock provided a brief summary of how the
perspectives of academics, clinicians, and regulatory bodies
pertain to (or diﬀer with) the current industrial imperatives
to develop new treatments for AD.
Regarding the conceptual problems with the disease
itself, Dr. Bullock mentioned that there are uncertainties
regarding the natural course of the amyloid deposition
process, particularly in light of recent evidence that suggests
amyloid levels may actually decline across time. Accordingly,
Dr. Bullock asserted that if the clinical impairments continue
to increase in severity without an apparent increase in brain
amyloid then certainly there are other processes at work
that must be more fully understood. This also relates to the
concernswiththescience,whichDr.Bullockalsomentioned,
particularly regarding the interpretation of ﬁndings derived
from the use of amyloid-imaging biomarkers such as the
Pittsburgh Imaging compound-B (PIB). Dr. Bullock also
echoed comments by the other presenters by stating that
currently available biomarkers still require considerable
validation to evaluate their relevance to clinical expression,
disease progression, and treatment responsiveness; that the
elaborate modes of action of certain proposed therapies have
not yet resulted in a robust “proof of concept;” and that
adequate translational (animal) models are still lacking.
Dr. Bullock also raised conceptual problems with the
investigational products by questioning the notion that “one
magic pill” could be developed to treat all of the problems
associated with AD. Although regulatory agencies may not
currently license products for the treatment of speciﬁc
symptoms, it may be useful to match modes of action
with speciﬁc clinical targets, thus narrowing the focus of
treatment development with the hope that such therapies
could potentially be used in combination. As an example,
Dr. Bullock mentioned that “apathy” can be among the
most bothersome symptoms for caregivers and treating this
speciﬁc symptom (among others) may be key to producing
“real-world” functional outcomes.
Dr. Bullock then turned to a discussion of speciﬁc
methodological issues such as whether it is appropriate to
employ the same scales and designs to measure disease-
modifying agents as have been used to assess symptomatic
treatment eﬀects. While such methods were designed pri-
marily to monitor increasing disabilities, it would be nice to
have designs or measures which would be more sensitive to
improvements in functioning, particularly when focusing on
the early stages of AD, during which cognitive impairments
are relatively minimal. Dr. Bullock noted that he favors
the use of measures to assess functional abilities, including
activities of daily livings (ADLs) or dependency scales (about
which he noted colleague Yaakov Stern may soon release
seminal ﬁndings). Dr. Bullock also recommended that more
emphasis be placed on measures of cognition which may
relatemoredirectlytofunctionalabilities,particularlyassess-
ments that may be more sensitive to the relations between
“executive control” processes and ADLs. Speciﬁcally, he
suggested that treatments which improve “executive control”
over global brain functions (not just “executive functions”
as typically measured by “frontal-lobe,” performance-type
tests) may be mirrored by greater improvements in ADLs,
than might a treatment which only aﬀects discrete memory
processes. Dr. Bullock also noted that he favors “person-
centered” clinical measures such as the Goal-Attainment
Scaling (GAS) developed by Rockwood et al. [5, 6].
In closing, Dr. Bullock reviewed some concerns with
the drug development process, in general, and posed some
suggestions for moving forward. Speciﬁcally, he noted that
in the haste to develop new products too many “positive”
phase II safety studies have resulted in “negative” phase III
eﬃcacy studies. He stated that, ﬁnancial imperatives aside,
some of the blame for this may reside with “unimaginative”
advisory boards or the circular exchangeof dialogue between
academic, industry, and regulatory representatives based on
ﬁxed ideas and vague expectations. As such, he challenged
each to be more vocal in their expression of dissenting
viewpoints when such are held and have not been voiced,
and encouraged a “regrouping” of what has already been
learned about AD so that better “more focused” clinical
targets may be revealed. He suggested that perhaps there are
toomanyquestionstobeansweredatonce,andthatfocusing
on answering the smaller questions ﬁrst may produce better
results. Finally, Dr. Bullock closed with a quotation from T.S.
Elliot: “Only those who risk going too far can possibly know
how far they can really go”.
6.Panel DiscussionwithDavidL.Streiner
Following theﬁnallecture,Drs.Grossberg, Arnold, Romano,
Ryan, and Bullock were joined on stage by an additional
academic discussant, David L. Streiner, who is the Research
Director at the Baycrest Centre, Professor of Psychiatry at the
UniversityofToronto,ProfessorofPsychiatryandBehavioral
Neurosciences, and Emeritus Professor of Clinical Epidemi-
ology and Biostatistics at McMaster University School of
Medicine.Beforeopeningtheﬂoorforapaneldiscussion,Dr.
Grossberg asked Dr. Streiner to provide his own perspective
on the topics raised in the session.
Dr. Streiner noted that there are many parallels with the
ﬁeld of schizophrenia research regarding the heterogeneity
of the population that is currently being deﬁned by a
constellation of symptoms that are collectively referred to
as one disease entity, namely AD. Although many clinically
distinct diagnostic variations of dementia exist (e.g., Lewy-
body dementia, or frontal-lobe dementia), there may yet be
many other subtypes of AD that would need to be distin-
guished by diﬀering etiologies to make meaningful progress
in the ﬁeld. Dr. Streiner also mentioned that he had detected
disagreement among the presenters (although not explicitlyInternational Journal of Alzheimer’s Disease 7
stated)concerningwhethertofocusprimarilyonbiomarkers
or functional measures of behavior as eﬃcacy endpoints.
As a statement of his perspective on this issue, Dr. Streiner
suggested that AD patients are not institutionalized because
ofabnormalMRIorlaboratoryresultsbutbecausethefamily
cannot cope with the behavioral or functional impairments.
Further, as there is currently a dearth of evidence showing
any causal relations between the purported biomarkers and
functional behaviors, he believes that biomarkers should
remain secondary measures for clinical trials.
The panel then ﬁelded questions from the audience,
leading to many intriguing discussions. Among the many
knowledgeable session attendees who posed questions, Lon
S. Schneider (University of Southern California, Keck School
of Medicine) noted that the dynamic interplay between
industryandacademiahasprovidedaparticulardeﬁnitionof
“mildtomoderateAD”thatpresentsalargemarketopportu-
nity, but that more focus should be directed toward deﬁning
sources of patient heterogeneity and distinguishing subtypes
of dementia that may prove even more relevant for both
industrial and academic research purposes. Regarding this
topic, Cristina Sampaio (Faculdade de Medicina de Lisboa)
mentioned that although it may currently be impossible
to accurately identify certain subpopulations (particularly,
“at-risk” or “pre-dementia” cases), this would not preclude
regulatoryagenciesfromconsideringtrialsdirectedatcertain
readily identiﬁable subpopulations (e.g., “familial-type” AD,
or APOE ε4 carriers) or other biomarker-deﬁned subtypes,
once they have been properly validated. Thus, Dr. Sampaio
(an academic regulatory reviewer, herself) challenged the
notion that regulatory agencies have narrowed the focus of
drug development to the “mild to moderate AD” deﬁnition
and encouraged industry to move beyond this particular
paradigm. Further, Dr. Sampaio also disagreed that reg-
ulatory agencies would not consider treatments targeting
speciﬁc symptoms, though she did note that establishing
the case for a particular symptom such as “apathy” would
be diﬃcult considering the common comorbid presentation
of depression. As an example, she noted that cognition in
schizophrenia has been established as a valid target indica-
tion, but only after thorough validation of the construct as a
corecharacteristicoftheillnessandtheidentiﬁcationofvalid
instruments to quantify changes in this particular symptom.
Additionalsessionattendeeswhoraisedinterestingtopics
of discussion included, Andrew C. Leon (Weill Medical
College of Cornell University), Ravi Anand (Anand Pharma
Consulting), and Suzanne Hendrix (Pentara Corporation),
whoeachstimulateddetaileddiscussionsregardingstatistical
issues, such as the implications of both attrition and
“competingrisks”onmodelingslopes,thesubtledistinctions
between “missing at random” and “missing not at random”
whenusingmixed-eﬀectsmodels,andtheneedforsensitivity
analyses to test whether the model can account for attrition
with either outcomes captured prior to drop-out or other
post-randomization predictors. Steven G. Potkin (University
of California, Irvine School of Medicine) mentioned that the
dissociation of biomarkers (e.g., neuroimaging measures)
from clinical expression may not be a troubling ﬁnding,
s i n c es u c hm e a s u r e sm a ya c t u a l l yp r o v i d em o r es e n s i t i v i t y
to potential disease-modifying eﬀects earlier in the course of
treatment than may clinical measures. Finally, Johannes Str-
eﬀer (Johnson & Johnson Pharmaceutical Research) noted
that it is critically important to acknowledge that biomarkers
must be validated with a speciﬁc purpose in mind, as a
valid biomarker for diagnostic purposes may or may not
have appropriate utility to also track progression or disease
modiﬁcation and vice versa.
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